17 November 2026
The electrocardiogram, a test performed every day in clinics and hospitals, can now help detect two heart diseases that are often diagnosed late: heart failure and transthyretin amyloid cardiomyopathy (ATTR-CM).
Willem 2.0 has received CE marking, making it the first and only AI in Europe to help detect both heart failure and ATTR cardiac amyloidosis from a routine ECG.
How it works
Willem analyses the ECG and identifies signals associated with these diseases that are invisible to the human eye. When it flags a patient as highly suspicious, the doctor can refer them sooner to the tests that confirm the diagnosis, such as echocardiography or cardiac scintigraphy.
%402x%20(1).png)
Years to a diagnosis
Around 40% of patients with heart failure had already visited their primary care doctor with symptoms in the five years before diagnosis¹. For cardiac amyloidosis, a much less known disease, the path is even longer: more than five years from first symptoms to diagnosis, with around 26 medical visits in the last three years alone². Detecting these diseases earlier means treatment can start when the prognosis is better, and hospital admissions can be avoided.
Many of these patients spend years going from appointment to appointment, and there’s already an ECG in their medical record. Willem helps doctors see in that test what they couldn’t see before
— Manuel Marina-Breysse, cardiologist, CEO and co-founder of Idoven.
%402x.png)
Validated in hospitals across Europe and the United States
Willem has been tested on more than 35,000 patients from hospitals in Europe and the United States, using data it had never seen before, and its results were compared with confirmatory diagnostic tests. In 9 out of 10 patients in whom Willem detected heart failure or amyloidosis, those tests confirmed the disease, which can help doctors refer the right patients sooner and with more confidence³.
For amyloidosis, the first validation phase was carried out at Hospital Universitario Puerta de Hierro, in collaboration with AstraZeneca, and has been published in the scientific journal Heart Rhythm.
Technical information
- Willem is a clinical decision support tool. Its results are reviewed by a healthcare professional and confirmed with the appropriate tests.
- Willem has been CE-marked for arrhythmia analysis since 2024. With Willem 2.0, it analyses 29 cardiac patterns and adds detection of heart failure and cardiac amyloidosis, in both hereditary and wild-type forms.
- For heart failure and amyloidosis, it uses the standard 12-lead resting ECG. For arrhythmias, it works with almost any ECG device.
- It integrates with the systems hospitals and device manufacturers already use.
LEGAL NOTICE: USE ONLY FOR HEALTHCARE PROFESSIONALS. Willem interpretation results are not intended to be the sole means of diagnosis or replace traditional methods of treatment. It is offered on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Please see Instructions of use for extended information about the product. 1. AstraZeneca Spain. CONCERTO press release, 28 May 2025. 2. Data on file. Idoven. Willem CE marking clinical validation. 3. Savarese G, et al. Cardiovasc Res. 2022;118:3272-87. doi:10.1093/cvr/cvac013. 4. Shahim B, et al. Card Fail Rev. 2023;9:e11. doi:10.15420/cfr.2023.05.
1. Heart Failure Diagnosis in the General Community – Who, How and When? A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, European Journal of Heart Failure 2023.
2. Mitchell JD et al., Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy, Journal of the American Heart Association 2026.
3. Willem 2.0 clinical validation data submitted for CE marking (Idoven, 2026).
.png)


.png)

.png)
.png)
.png)



